SK Chemical recently received sales approval of the treatment of rare diseases 'Replagal inj’

On August 25, according to the related industry, SK Chemical recently received sales approval of the treatment of rare diseases 'Replagal inj (α-galactosidase A)' from the Minister of Food and Drug Safety.

Replagal is the treatment with long-term enzyme replacement therapy indicated for patients diagnosed with Fabry disease (α-galactosidase A deficiency).

Replagal is the third Fabry disease t...